L3VLUP
ProSign in

ELAN · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

ELANVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • ELAN
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterELANVRTX
Q3 20206 holders, $2.9bn31 holders, $21.9bn
Q4 202016 holders, $4.1bn30 holders, $18.4bn
Q1 202112 holders, $4.0bn31 holders, $15.4bn
Q2 202114 holders, $4.6bn30 holders, $12.7bn
Q3 202110 holders, $4.0bn35 holders, $10.1bn
Q4 202113 holders, $3.8bn28 holders, $12.4bn
Q1 202211 holders, $3.1bn23 holders, $16.1bn
Q2 202211 holders, $2.4bn25 holders, $18.1bn
Q3 202215 holders, $1.9bn22 holders, $18.4bn
Q4 202215 holders, $1.7bn28 holders, $18.4bn
Q1 202312 holders, $1.2bn26 holders, $21.4bn
Q2 202313 holders, $1.6bn27 holders, $24.7bn
Q3 202312 holders, $1.7bn33 holders, $24.3bn
Q4 20239 holders, $1.9bn32 holders, $28.6bn
Q1 202410 holders, $2.3bn31 holders, $29.8bn
Q2 20249 holders, $2.1bn29 holders, $33.4bn
Q3 20247 holders, $1.5bn27 holders, $33.5bn
Q4 20245 holders, $1.5bn26 holders, $28.5bn
Q1 20256 holders, $1.5bn21 holders, $35.4bn
Q2 20259 holders, $2.5bn21 holders, $32.3bn
Q3 202512 holders, $3.4bn22 holders, $25.9bn
Q4 20259 holders, $3.3bn26 holders, $31.8bn
Q1 20265 holders, $3.0bn25 holders, $31.8bn
Q2 202610 holders, $3.6bn26 holders, $34.6bn
ELAN

Elanco Animal Health Inc

Holders
5
Reported value
$3.0bn
Buyers
15
Sellers
16

Breadth -1 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
VRTX

Vertex Pharmaceuticals Inc

Holders
25
Reported value
$31.8bn
Buyers
17
Sellers
21

Breadth -4 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q1 2026

Among the 27 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only ELAN (2)

Dodge & Cox, Maverick Capital Ltd

Only VRTX (22)

Acadian Asset Management LLC, AllianceBernstein LP, Arrowstreet Capital LP, Baillie Gifford & Co, Bridgewater Associates LP, Capital Research Global Investors, Caxton Associates LLP, D. E. Shaw & Co., Holocene Advisors LP, Hudson Bay Capital Management LP, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, MFS Investment Management, Neuberger Berman Group LLC, Renaissance Technologies LLC, T. Rowe Price Associates Inc, Two Sigma Investments LP, Walleye Capital LLC, Wellington Management Group LLP, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →